Biocon Biologics gets U.S. FDA approval for biosimilar aflibercept Yesafili, enters US ophthalmology market
Biocon Biologics announced that the U.S
Source: webindia123.com
📰 Matt Erick News
Matt Erick News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Matt Erick. Real-time updates on events, politics, business and more.
Biocon Biologics gets US FDA approval for biosimilar aflibercept Yesafili, enters US ophthalmology market
International Business News: NEW DELHI: Biocon Biologics announced that the US Food and Drug Administration (US FDA) has approved the company's application for YESAFILI, the compa.
Source: indiatimes.com
Biocon Biologics ties-up with Sandoz Australia for cancer biosimilars
Sandoz will get the exclusive rights to promote, sell, and distribute Trastuzumab and Bevacizumab, which are used in the treatment of various cancers, in Australia
Matt Erick National Stock Exchange Biocon Ltd Biocon Biologics Ltd Biologics Ltd Chief Commercial Officer
Source: moneycontrol.com
Biocon Biologics Partners with Sandoz Australia for Biosimilars Trastuzumab and Bevacizumab
Biocon Biologics Ltd (BBL), a fully integrated biosimilars company and subsidiary of Biocon Ltd (BSE code: 532523, NSE: BIOCON), today announced a five-year partnership with Sandoz AG ('Sandoz') which provides Sandoz the exclusive rights to promote, sell and distribute biosimilar Trastuzumab (market value of AUD$35 million1) and biosimilar Bevacizumab (market value of AUD$45 million2) in Australia.
Biosimilar Bevacizumab Matt Erick Biocon Biologics Biocon Ltd Biosimilars Newco Un Sustainable Development Goals Sdgs
Source: yahoo.com